Celiac Disease Drugs Market
Outlook: A sea of opportunity beckons
However, stringent regulatory
frameworks for drug approval is a major restraint for growth of the global Celiac
Disease Drugs Market. Regional segmentation by Coherent Market Insights
comprises North America, Europe, Asia Pacific, Latin America, Middle East, and
Africa. According to the University of Chicago Medicine, Celiac Disease Center,
approximately 1% of healthy average Americans are affected by celiac disease.
In 2007, 3 million individuals were affected with Celiac Disease and 97% people
are undiagnosed and untreated. Around 3 million people were suffering from
diabetes type1, out of which 6% (180,000) also had celiac disease; around
610,000 unexplained infertility cases were reported, out of which 6% also
suffered from celiac disease. The prevalence of celiac disease in the U.S. in
healthy people is 1 in 133 and is estimated at 1 in 56 in people with related
symptoms. People with first degree and second degree relatives suffering from
celiac disease are 1 in 22 and 1 in 39, respectively. This creates highly
lucrative growth opportunities for players in the global celiac disease drugs
market, post clinical trials approval. Asia Pacific is likely to show high
growth rates in the years post drug approval in the global celiac disease drugs
industry, with China and India being the highest revenue contributors.
Celiac disease is an autoimmune
disorder that mainly affects the small intestine. It is mainly observed in
individual who are hereditarily inclined towards gluten. Celiac disease
symptoms include gastrointestinal malfunction such as diarrhea, abdominal
distention, loss of appetite, and among kids failure to grow normally and also
sometimes loss of lymphocytes.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/168
Coeliac disease is triggered by a
bodily reaction to gluten, generally found in wheat and in other grains such as
barley and rye. As the mechanism of action is still shrouded in an air of
uncertainty, many pharmaceutical companies are conducting clinical trials to
develop specific products to treat celiac disease. The success of the celiac
drug innovation would be a big milestone for any pharmaceutical company in
celiac disease drugs market.
100% gluten-free diet is the only
existing treatment for celiac disease
According to National Foundation
for Celiac Awareness (NFCA), celiac disease affects both men and women of all
age groups and races. It is estimated that around 83% of all local Americans
who have celiac disease are untreated or misdiagnosed with other bowel
disorders. People with untreated celiac disease incur additional average
medical costs of US$ 3,964 as compared to healthy individuals. Of all the
people diagnosed with celiac disease, 5-22% have an immediate family member who
was diagnosed with celiac disease. There are no specific drugs to treat celiac
diseases. The total number of individuals diagnosed in the U.K. with celiac
disease has increased fourfold between 1990 and 2011, from 5.2 per 100,000 to
19.1 per 100,000. This inadvertently creates a highly conducive environment for
growth of the celiac disease drugs market, once such a drug is commercialized
in the market.
Celiac Disease Drugs Market
Scenario: Bowel biopsy the only available method to confirm celiac disease
The celiac disease drugs are
still undergoing clinical trials. It is challenging to identify celiac disease
in the primary stages, as the symptoms are deceptively similar to those of
other bowel disorders. Various subtle and selective blood tests such as
anti-tissue transglutaminase antibodies are used to screen the disease. If the
test results are positive, then the individual is asked to undergo a small
bowel biopsy to confirm the disease, as there is no specific or defined
treatment. Extensive R&D activities currently underway are expected to pave
way for more effective and advanced diagnostic options and innovative drugs, in
turn positioning the global celiac disease drugs market on high growth
trajectory.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/celiac-disease-drugs-market-168
Major players in the Global
Market
Key players operating the market
include Alvine Pharmaceuticals, Inc., Alba Therapeutics Corporation, ImmusanT,
and the Institute for Protein Design. All the above mentioned companies have
their celiac disease drugs in clinical trial phase I and II.
Key Developments in the Global
Market
Key players in the market are
focused on approval and launch of novel drugs intended for the treatment of
celiac disease. For instance, in August 2019, ActoBio Therapeutics, Inc., a
wholly owned subsidiary of Intrexon Corporation, announced that the U.S. Food
and Drug Administration (FDA) granted an Investigational New Drug (IND) application
for AG017, an orally-delivered drug for the treatment of celiac disease.
Moreover, in August 2019,
Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company based
in the U.S., announced first patient enrollment in its Phase III clinical
trial, CeD LA 3001 for Larazotide acetate, a drug candidate for the treatment
of celiac disease.
Major institutes and universities
are focused on R&D activities related to celiac disease. For instance, in
August 2019, researchers from the Massachusetts General Hospital and The Walter
and Eliza Hall Institute, Australia, found that gluten-specific CD4+ T cells
are rapidly reactivated by antigen -exposure likely causing celiac
disease-associated gastrointestinal symptoms. The development is expected to offer
diagnostic blood test for celiac disease.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/168
About
Coherent Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment